Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 6,683 matching trials from the live ClinicalTrials.gov search.

Filters: Stanford, California Clear all

Conditions: Glioma
Interventions: Dordaviprone (ONC201); Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 9
States / cities: San Francisco, California • Stanford, California • Ann Arbor, Michigan + 5 more

Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions: Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 1,895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 191
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more

Conditions: Augmented Renal Clearance (ARC), Systemic Inflammatory Response Syndrome (SIRS)
Interventions: Ceftaroline fosamil/Avibactam (CXL); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 19
States / cities: Fresno, California • Los Angeles, California • San Diego, California + 16 more

Conditions: Rib Fractures
Interventions: Lidocaine IV Infusion, 2% Lidocaine via ESPB; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Arthritis, Rheumatoid
Interventions: Adalimumab, CP-690,550, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 22
States / cities: Mesa, Arizona • Little Rock, Arkansas • Northridge, California + 17 more

Conditions: Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Minneapolis, Minnesota + 2 more

Conditions: Head and Neck Cancer
Interventions: Nivolumab, Ipilimumab, Cetuximab/Erbitux, Cisplatin/Platinol, Carboplatin/Paraplatin, Fluorouracil/Adrucil; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 947 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Duarte, California • Stanford, California + 16 more

Conditions: Progressive Glioblastoma, Recurrent Glioblastoma
Interventions: Biopsy Procedure, Biospecimen Collection, Lomustine, Magnetic Resonance Imaging, Nivolumab, Relatlimab, Surgical Procedure; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 325
States / cities: Jonesboro, Arkansas • Auburn, California • Duarte, California + 252 more

Conditions: Atrial Fibrillation, Abnormal Heart Rhythms
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Corona Virus Infection, Flu Vaccine, Immunity
Interventions: Flu shot; Biological
Lead sponsor: Stanford University; Other
Eligibility: 9 Years to 64 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Extraocular Retinoblastoma
Interventions: Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Radiation Therapy, Thiotepa, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more

Conditions: Non-small Cell Lung Cancer
Interventions: Erlotinib, Hydroxychloroquine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2027
U.S. locations: 4
States / cities: Stanford, California • New Haven, Connecticut • Baltimore, Maryland + 1 more

Conditions: Acute Ischaemic Stroke, Transient Ischaemic Attack
Interventions: ticagrelor, Acetylsalicylic acid (ASA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 13,307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 115
States / cities: Montgomery, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 112 more

Conditions: Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions: Absorb BVS, XIENCE; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 98
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more

Conditions: Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Interventions: Intracept™ Intraosseous Nerve Ablation; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 22
States / cities: Flagstaff, Arizona • Phoenix, Arizona • Larkspur, California + 19 more

Conditions: Rheumatoid Arthritis
Interventions: GDC-0853, Adalimumab, Folic Acid, MTX, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more

Conditions: Prostate Cancer
Interventions: bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2025
U.S. locations: 499
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more

Conditions: Epithelial Ovarian Cancer
Interventions: CA125 assay on Abbott Architect i1000SR platform, HE4 assay on Architect i1000SR platform, Transvaginal Ultrasound; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 25 Years to 80 Years · Female only
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 5
States / cities: Duarte, California • Los Angeles, California • Stanford, California + 2 more

Conditions: Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders, Depression Disorder, Depression
Interventions: CYB003, Psychological Support; Drug · Behavioral
Lead sponsor: Cybin IRL Limited; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 43
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 36 more

Conditions: Recurrent Childhood Ependymoma
Interventions: Everolimus; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 4
States / cities: Stanford, California • New York, New York • Dallas, Texas + 1 more

Conditions: Anxiety Disorders, Mood Disorders
Interventions: Teleo, Standard videoconferencing; Other
Lead sponsor: Stanford University; Other
Eligibility: 5 Years to 14 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Aortic Aneurysm, Thoracic
Interventions: GORE® TAG® Thoracic Branch Endoprosthesis; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 6
States / cities: Stanford, California • Ann Arbor, Michigan • Rochester, Minnesota + 3 more

Conditions: Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more

Conditions: Overactive Bladder With Urge Urinary Incontinence
Interventions: URO-902, Placebo; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 20
States / cities: Mobile, Alabama • Tucson, Arizona • Laguna Hills, California + 17 more

Search by objective public record fields.

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance

Comparison of Continuous Intravenous Lidocaine Infusion Versus ESP Block for Rib Fracture Analgesia

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

COMparison of Physiological Algorithms for Real-time Evaluation of Atrial Fibrillation

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Absorb IV Randomized Controlled Trial

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Everolimus for Children With Recurrent or Progressive Ependymoma

Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings

Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence